Life Science Investing Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency
Life Science Investing AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib for Alopecia Areata
Life Science Investing AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Life Science Investing Ichnos Glenmark Innovation and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
Life Science Investing AbbVie and Ichnos Glenmark Innovation Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
Life Science Investing AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
Life Science Investing U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
Life Science Investing AbbVie Announces New Data Demonstrating Atogepant Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
Life Science Investing AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
